Larimar Therapeutics, Inc.
LRMR
$2.97
$0.113.85%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -29.28M | -28.82M | -15.50M | -21.63M | -14.65M |
| Total Depreciation and Amortization | 88.00K | 77.00K | 74.00K | 87.00K | 80.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.02M | 1.17M | 198.00K | 480.00K | 1.50M |
| Change in Net Operating Assets | 1.63M | 5.76M | -9.32M | 7.07M | 2.66M |
| Cash from Operations | -26.54M | -21.82M | -24.55M | -13.99M | -10.41M |
| Capital Expenditure | -49.00K | -179.00K | -62.00K | -274.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 14.50M | 19.38M | 27.33M | -63.22M | -68.36M |
| Cash from Investing | 14.45M | 19.20M | 27.27M | -63.49M | -68.36M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 36.00K | 30.00K | -- | 162.15M |
| Repurchase of Common Stock | -- | -- | -- | -334.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 36.00K | 30.00K | -334.00K | 162.15M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -12.09M | -2.58M | 2.76M | -77.81M | 83.38M |